Stock Track | Avita Therapeutics Soars 14.18% Intraday on Positive Interim Wound Care Study Results
Stock Track
Apr 15
Avita Therapeutics' stock soared 14.18% intraday following the release of positive interim data from a key clinical study.
The surge comes after the company reported interim results from its Cohealyx-I multi-center study, which showed a significant reduction in the mean time to skin grafting for patients with full-thickness wounds. The data indicated a mean time of 13.6 days compared to a 33.2-day real-world benchmark.
The positive clinical outcomes, including a median time to grafting of 11 days, are seen as a promising development for the company's wound care platform, driving investor optimism regarding its potential market application and future commercial success.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.